SynOx Therapeutics increases capital to USD 92 million in Series B financing

Gilde Healthcare leads Series B extension and supports Phase 3 TANGENT trial for emactuzumab, a promising CSF-1R-targeted therapy for tenosynovial giant cell tumor

Dublin, Ireland and Oxford, UK - October 30, 2024 - SynOx Therapeutics Limited, a late-stage clinical-stage biopharmaceutical company, today announced the completion of a Series B extension, bringing the total funding to $92 million. This expansion is led by new investor Gilde Healthcare and complements investments from Forbion, HealthCap and Bioqube Ventures. The capital will fund the TANGENT Phase 3 pivotal trial evaluating emactuzumab, an innovative antibody that specifically inhibits the CSF-1 receptor (CSF-1R) and was developed for the treatment of tenosynovial giant cell tumor (TGCT).

First patient dosing in global phase 3 study TANGENT

With the completion of the Series B extension, SynOx has dosed the first patients in the TANGENT study. This global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study is evaluating the efficacy and safety of emactuzumab in TGCT patients. The primary endpoint is objective response rate (ORR), and secondary endpoints such as quality of life, functionality, tumor volume and duration of response will also be measured. The trial will enroll approximately 130 patients, more information is available on ClinicalTrials.gov (Identifier: NCT05417789).

We are pleased to have Gilde Healthcare on board as a partner and appreciate their support of our team and vision to bring a better quality of life to TGCT patients worldwide

Ray Barlow, CEO of SynOx

TGCT: A rare but debilitating disease Tenosynovial giant cell tumor (TGCT) is a non-malignant but aggressively growing tumor of the synovium, mainly in the knee, hip and ankle joints, and is caused by excessive production of CSF-1. Patients suffer from chronic functional impairment of the joints, pain and limited mobility. Emactuzumab specifically inhibits CSF-1R and has shown in previous studies that it can provide fast and effective treatment with short treatment duration and long duration of action.

It is a pleasure to support SynOx in the late-stage development of emactuzumab. We believe that this antibody represents a first-in-class solution for TGCT and that the SynOx team is well positioned to successfully complete clinical development

Arthur Franken, General Partner at Gilde Healthcare

With the TANGENT study, SynOx aims to advance the development of emactuzumab and bring the drug to market for TGCT patients as soon as possible. Arthur Franken, General Partner at Gilde Healthcare, joins the SynOx board as part of the financing. He brings over twenty years of experience in venture and growth capital financing, including numerous successful IPOs and company sales.